For decades, the focus has been on lowering LDL cholesterol levels to reduce heart attack risk. However, recent studies suggest that measuring Apolipoprotein B (apoB) might offer a more accurate and nuanced approach.

The LDL test measures cholesterol within particles, but two people with the same level can have vastly different numbers of these harmful carriers. This gap has led researchers to look at apoB, which tracks the total number of cholesterol-carrying particles in the blood—potentially offering better risk identification.

Key players like the American Heart Association and European Atherosclerosis Society are recognizing this shift. A 2026 study by McGill University’s Allan Sniderman found that using apoB to guide treatment decisions could prevent more heart attacks than current methods, while remaining cost-effective. Yet, LDL remains the primary player due to its simplicity and proven success in lowering cholesterol.

The complexity of cholesterol continues to evolve, as recent studies show that even statin-takers with high levels of apoB face increased risk. This highlights the necessity for a more comprehensive approach—a shift that could involve testing multiple markers like LDL, remnant cholesterol, and lipoprotein(a).